Display Settings:

Format

Send to:

Choose Destination
Int J Clin Pract Suppl. 2011 Jan;(169):8-10. doi: 10.1111/j.1742-1241.2010.02606.x.

Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead.

Author information

  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Abstract

Since the identification of the link between pulmonary arterial hypertension (PAH) and exposure to certain drugs and toxins nearly fifty years ago, the expanding landscape of available pharmaceuticals and illicit drugs is further fueling this association. While some causative agents in drugs and toxins associated PAH (D&T-APAH) have been identified, little is known about the exact biology and clinical implications of the disease. In this review, we discuss the historical evidence that links PAH with exposure to anorexinogens, cocaine, and methamphetamines and concentrate on what is known about potential pathogenesis, clinical manifestations, and current management. We conclude that future research should focus on studies looking at clinical outcome and susceptibility factors.

© 2010 Blackwell Publishing Ltd.

PMID:
21176010
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk